General Information of Drug Transporter (DT)
DT ID DTD0319 Transporter Info
Gene Name SLC36A2
Transporter Name Proton-coupled amino acid transporter 2
Gene ID
153201
UniProt ID
Q495M3
Post-Translational Modification of This DT
Overview of SLC36A2 Modification Sites with Functional and Structural Information
Sequence
PTM type
X-Phosphorylation X: Amino Acid

Phosphorylation

  Serine

        12 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC36A2 [1]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

2

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 2 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC36A2 [1] , [2]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

6

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 6 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLC36A2 [3]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

22

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 22 has the potential to affect its expression or activity.

  PTM Phenomenon 4

Have the potential to influence SLC36A2 [3]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

26

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 26 has the potential to affect its expression or activity.

  PTM Phenomenon 5

Have the potential to influence SLC36A2 [1] , [2]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

41

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 41 has the potential to affect its expression or activity.

  PTM Phenomenon 6

Have the potential to influence SLC36A2 [1]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

43

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 43 has the potential to affect its expression or activity.

  PTM Phenomenon 7

Have the potential to influence SLC36A2 [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

228

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 228 has the potential to affect its expression or activity.

  PTM Phenomenon 8

Have the potential to influence SLC36A2 [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

234

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 234 has the potential to affect its expression or activity.

  PTM Phenomenon 9

Have the potential to influence SLC36A2 [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

238

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 238 has the potential to affect its expression or activity.

  PTM Phenomenon 10

Have the potential to influence SLC36A2 [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

254

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 254 has the potential to affect its expression or activity.

  PTM Phenomenon 11

Have the potential to influence SLC36A2 [5]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

261

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 261 has the potential to affect its expression or activity.

  PTM Phenomenon 12

Have the potential to influence SLC36A2 [5]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

384

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Serine 384 has the potential to affect its expression or activity.

  Threonine

          3 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC36A2 [6]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

70

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Threonine 70 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC36A2 [4]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

225

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Threonine 225 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLC36A2 [4]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

247

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Threonine 247 has the potential to affect its expression or activity.

  Tyrosine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC36A2 [4]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

245

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Tyrosine 245 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC36A2 [7] , [8]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

318

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC36A2 Tyrosine 318 has the potential to affect its expression or activity.
References
1 Identification of Missing Proteins in the Phosphoproteome of Kidney Cancer. J Proteome Res. 2017 Dec 1;16(12):4364-4373.
2 A fast sample processing strategy for large-scale profiling of human urine phosphoproteome by mass spectrometry. Talanta. 2018 Aug 1;185:166-173.
3 Quantitative global phosphoproteomics of human umbilical vein endothelial cells after activation of the Rap signaling pathway. Mol Biosyst. 2013 Apr 5;9(4):732-49.
4 In situ sample processing approach (iSPA) for comprehensive quantitative phosphoproteome analysis. J Proteome Res. 2014 Sep 5;13(9):3896-904.
5 Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
6 iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012 Jun;11(6):M111.014423.
7 Systematic functional prioritization of protein posttranslational modifications. Cell. 2012 Jul 20;150(2):413-25.
8 Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007 Dec 14;131(6):1190-203.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.